A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD) | MicrobiomeTrials
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-07-21Est. Completion: 2029-04-27
Enrollment target: 35 participants
Locations
Children's Hospital Los Angeles, Los Angeles, California, United States
Children's Hospital Colorado, Aurora, Colorado, United States
Johns Hopkins Hospital, Baltimore, Maryland, United States
Boston Children's Hospital, Boston, Massachusetts, United States
M Health Fairview Masonic Children's Hospital, Minneapolis, Minnesota, United States
Nationwide Children's Hospital, Columbus, Ohio, United States
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Fundacion Respirar, CABA, Argentina
Women's and Children's Hospital, North Adelaide, South Australia, Australia
Brussels - UNIV HUDERF, Brussels, Belgium
Serviços Medicos Respirar Sul Fluminense, Barra Mansa, Brazil
Associação dos Funcionários Públicos do Estado do Rio Grande do Sul - Hospital Ernesto Dorneles, Porto Alegre, Brazil
IMIP Pernambuco, Recife, Brazil
Centro de Pesquisa Clinica do Instituto da Crianca - HCFMUSP, São Paulo, Brazil
Alberta Children's Hospital, Calgary, Alberta, Canada
The Hospital for Sick Children, Toronto, Ontario, Canada
Other microbiome trials you might be interested in